Paul Grayson

Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA

Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Part of 5AM Venture Management LLC, RuiYi, Inc. (China) is a Chinese company that develops biologic therapies. The company is based in Pudong, China. The CEO of the company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio Sub, Inc., part of 5AM Venture Management LLC from December 11, 2023 on March 22, 2012.

Progenitor Labs Ltd. develops drugs to regenerate specific tissues of the human body in response to injury, disease, and ageing. Its products include ProScreen and CombiCult. The company was founded by Yen Choo on February 12, 2010 and is headquartered in Stevenage, the United Kingdom.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA.

Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024.